Clinical Trial Update: Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

AstraZeneca-sponsored Phase 2 trial evaluating oral AZD2423 (100 mg) in adults with mild chronic obstructive pulmonary disease; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD2423

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease, Lung Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-10-23